]>
IRCT20180218038782N1 IRCT 2018-09-09 Iran University of Medical Sciences The efficacy of cue exposure therapy on treatment outcome of stimulant use disorder The efficacy of cue exposure therapy on treatment outcome of stimulant use disorder 2018-09-06 anticipated 40 Complete https://irct.ir/trial/29702 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Factorial, Purpose: Education/Guidance, Randomization description: simple randomization by app or websites, Blinding description: patients will not get any informations about assignment process. N/A stimulant use disorder. Intervention 1: Intervention group: cue exposure treatment. Intervention 2: Control group: treatment as usual (TAU). Yes - There is a plan to make this available What will be shared: all of data will be available with regard to confidentiality principle When: starting 6 months after publication To whom: only for researchers Conditions: those researchers interested to re analysis or doing meta analysis can request for receiving data Where to obtain: to get data they should send a request to email address of Talebizadeh: talebizadeh.m86@gmail.com How to obtain: researchers should note why they need data files and how they are going to use them. Comments:
public Meghdad Talebizadeh
No 1. Tehran Psychiatric Institute, School of Behavioral Sciences and Mental Health, mansouri ave, Niayesh st. satarkhan st. tehran
Tehran Iran (Islamic Republic of) 1445613111 +98 21 6655 1655 talebizadeh.m86@gmail.com Iran University of Medical Sciences scientific Meghdad Talebizadeh
No 1. Tehran Psychiatric Institute, School of Behavioral Sciences and Mental Health, mansouri ave, Niayesh st. satarkhan st. tehran
Tehran Iran (Islamic Republic of) 1445613111 +98 21 6655 1655 talebizadeh.m86@gmail.com Iran University of Medical Sciences Iran (Islamic Republic of) stimulant use disorder diagnosis not using any kind of drug except of nicotine within two weeks before program starting Ability of reading and writing persian language Completion of informed consent form 18 years 64 years Male having sever suicidal ideation having psychotic symptoms having acute physical problems F15.2 Other stimulant dependence Behavior Behavior Intervention group: cue exposure treatment Control group: treatment as usual (TAU) Treatment outcome includes: addiction severity, craving, relapse rate, quality of life and severity of depression, anxiety and stress that will be measured by addiction severity index (ASI), Desires for Drug Questionnaire (DDQ), Obsessive Compulsive Drug Use Scale (OCDUS), urine test, World Health Organization Quality of Life-Brief (WHOQOL-BREF) and Depression Anxiety Stress Scales (DASS-21). Timepoint: assessment will complete at pre-test, post-test and follow up (3 months after treatment completion). Method of measurement: addiction severity index (ASI), Desires for Drug Questionnaire (DDQ), Obsessive Compulsive Drug Use Scale (OCDUS), urine test, World Health Organization Quality of Life-Brief (WHOQOL-BREF) and Depression Anxiety Stress Scales (DASS-21). Addiction severity. Timepoint: pretest, post test, 3 months follow up. Method of measurement: addiction severity index (ASI). Craving. Timepoint: pretest, post test, 3 months follow up. Method of measurement: Desires for Drug Questionnaire (DDQ) and Obsessive Compulsive Drug Use Scale (OCDUS). Relapse rate. Timepoint: pretest, post test, 3 months follow up. Method of measurement: urine test. Quality of life. Timepoint: pretest, post test, 3 months follow up. Method of measurement: World Health Organization Quality of Life-Brief (WHOQOL-BREF). Severity of depression, anxiety and stress. Timepoint: pretest, post test, 3 months follow up. Method of measurement: Depression Anxiety Stress Scales (DASS-21). Iran University of Medical Sciences Approved 2018-03-18 Ethics commitee of Iran univeristy of medical siences Deputy of research and technology, Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran,IRAN. Tehran Tehran Iran (Islamic Republic of)